Calculus Capital Ltd. — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Trogenixtrogenixbio.cominOct 2025
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesEdinburgh, GB
Ken Macnamarain
Co-investorsACADEMY INVESTORAIN VenturesIQ CapitalLongeVCOld College Capital4BIO Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



.jpeg)

